CU20110030A7 - Compuestos orgánicos - Google Patents
Compuestos orgánicosInfo
- Publication number
- CU20110030A7 CU20110030A7 CU20110030A CU20110030A CU20110030A7 CU 20110030 A7 CU20110030 A7 CU 20110030A7 CU 20110030 A CU20110030 A CU 20110030A CU 20110030 A CU20110030 A CU 20110030A CU 20110030 A7 CU20110030 A7 CU 20110030A7
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- organic compounds
- formula
- cxcr2
- mediators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/52—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Furan Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
La presente invención se refiere a los compuestos de la fórmula (I): ESPACIO PARA LA FÓRMULA en donde X, R1, R2, R3, R4 y R5 son como se definen en la presente, los cuales son útiles para el tratamiento de enfermedades que respondan a los mediadores del receptor CXCR2. También se describen composiciones farmacéuticas que contienen los compuestos, y procesos para la preparación de los compuestos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08161765 | 2008-08-04 | ||
US16162709P | 2009-03-19 | 2009-03-19 | |
PCT/EP2009/060061 WO2010015613A1 (en) | 2008-08-04 | 2009-08-03 | Organic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20110030A7 true CU20110030A7 (es) | 2011-12-28 |
CU24038B1 CU24038B1 (es) | 2014-11-27 |
Family
ID=39769571
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2011000030A CU24038B1 (es) | 2008-08-04 | 2011-02-04 | Derivados de sulfonamidas útiles para el tratamiento de enfermedades que respondan a los mediadores del receptor cxcr2 |
CU20110142A CU20110142A6 (es) | 2008-08-04 | 2011-06-24 | Procedimiento para tratar enfermedades inflamatorias o alérgicas |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20110142A CU20110142A6 (es) | 2008-08-04 | 2011-06-24 | Procedimiento para tratar enfermedades inflamatorias o alérgicas |
Country Status (35)
Country | Link |
---|---|
US (5) | US7989497B2 (es) |
EP (1) | EP2310359B1 (es) |
JP (1) | JP5303645B2 (es) |
KR (1) | KR101310503B1 (es) |
CN (1) | CN102171183B (es) |
AR (1) | AR075071A1 (es) |
AU (1) | AU2009279123B2 (es) |
BR (1) | BRPI0916995B8 (es) |
CA (1) | CA2732932C (es) |
CO (1) | CO6341623A2 (es) |
CU (2) | CU24038B1 (es) |
DK (1) | DK2310359T3 (es) |
EA (1) | EA020374B1 (es) |
EC (1) | ECSP11010804A (es) |
ES (1) | ES2458596T3 (es) |
HK (1) | HK1155151A1 (es) |
HN (1) | HN2011000341A (es) |
HR (1) | HRP20140350T1 (es) |
IL (1) | IL210836A (es) |
JO (1) | JO2910B1 (es) |
MA (1) | MA32536B1 (es) |
MX (1) | MX2011001378A (es) |
MY (1) | MY155626A (es) |
NZ (1) | NZ590708A (es) |
PE (1) | PE20110205A1 (es) |
PL (1) | PL2310359T3 (es) |
PT (1) | PT2310359E (es) |
RS (1) | RS53264B (es) |
SI (1) | SI2310359T1 (es) |
SV (1) | SV2011003831A (es) |
TW (1) | TWI430791B (es) |
UA (1) | UA103198C2 (es) |
UY (1) | UY32025A (es) |
WO (1) | WO2010015613A1 (es) |
ZA (1) | ZA201100512B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
US8648070B2 (en) * | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
AU2016201916A1 (en) * | 2011-09-02 | 2016-04-21 | Novartis Ag | Choline salt of an anti-inflammatory substituted cyclobutenedione compound |
US9018261B2 (en) * | 2011-09-02 | 2015-04-28 | Novartis Ag | Choline salt of an anti-inflammatory substituted cyclobutenedione compound |
FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
FR2981935B1 (fr) * | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
CN110420316A (zh) | 2013-06-18 | 2019-11-08 | 纽约大学 | 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点 |
FR3030515B1 (fr) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Cxcr2抑制劑 |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
RU2020106383A (ru) * | 2017-08-14 | 2021-09-16 | Аллерган, Инк. | 3,4-двузамещенные 3-циклобутен-1,2-дионы и их применение |
KR20200089286A (ko) | 2017-11-16 | 2020-07-24 | 노파르티스 아게 | 조합 요법 |
EP3737366A4 (en) | 2018-01-08 | 2022-07-27 | ChemoCentryx, Inc. | METHOD OF TREATMENT OF GENERALIZED PUSTULOUS PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2 |
WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
EA202190586A1 (ru) | 2018-09-21 | 2021-07-05 | Пфайзер Инк. | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 |
CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
EA202192029A1 (ru) | 2019-02-15 | 2021-10-27 | Новартис Аг | Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения |
KR20210129671A (ko) | 2019-02-15 | 2021-10-28 | 노파르티스 아게 | 3-(1-옥소-5-(피페리딘-4-일)이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도 |
CN112759549B (zh) * | 2019-11-05 | 2023-07-28 | 中国医学科学院药物研究所 | 3-取代氨基-4-((取代吡啶基)氨基)环丁-3-烯-1,2-二酮类化合物 |
CN112851635B (zh) * | 2019-11-28 | 2022-09-16 | 中国医学科学院药物研究所 | 环状砜类化合物及其制备方法、用途和药物组合物 |
EP4076660A1 (en) | 2019-12-20 | 2022-10-26 | Novartis AG | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354763A (en) * | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
US6166050A (en) * | 1998-12-14 | 2000-12-26 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4 |
CA2349832A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
EP1351933B1 (en) | 2001-01-16 | 2006-11-22 | SmithKline Beecham Corporation | Il-8 receptor antagonists |
EP1383488A2 (en) | 2001-03-30 | 2004-01-28 | SmithKline Beecham Corporation | Methods of synthesizing phenol-containing compounds |
US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
US7132445B2 (en) * | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
CA2444031C (en) | 2001-04-16 | 2012-02-21 | Schering Corporation | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
CA2479126C (en) | 2002-03-18 | 2011-11-15 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
PE20051093A1 (es) | 2004-01-30 | 2006-01-16 | Schering Corp | Polimorfos cristalinos de un ligando receptor de cxc quimiocina |
DE102005001053A1 (de) * | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Quadratsäurederivate |
DE502006002325D1 (de) | 2005-02-10 | 2009-01-22 | Wacker Chemie Ag | Lacke enthaltend partikel mit geschützten isocyanatgruppen |
WO2006088920A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
DE102005035742A1 (de) | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
CN101511809A (zh) | 2006-07-07 | 2009-08-19 | 先灵公司 | 作为cxc-趋化因子受体配体的3,4-二取代的环丁烯-1,2-二酮 |
WO2008075353A1 (en) * | 2006-12-19 | 2008-06-26 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
MX2009013276A (es) * | 2007-06-06 | 2010-01-25 | Novartis Ag | Compuestos anti-inflamatorios de ciclobutenodiona sustituida. |
WO2009005801A1 (en) | 2007-07-03 | 2009-01-08 | Schering Corporation | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
WO2009005802A1 (en) | 2007-07-05 | 2009-01-08 | Schering Corporation | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
MX2010006089A (es) | 2007-12-04 | 2010-09-22 | Schering Corp | Metodos de tratamiento de enfermedad pulmonar obstructiva cronica. |
AR069637A1 (es) | 2007-12-10 | 2010-02-10 | Novartis Ag | Derivados de pirazinas |
UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
WO2010091543A1 (en) | 2009-02-10 | 2010-08-19 | Merck Sharp & Dohme Corp. | Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists |
US9018261B2 (en) | 2011-09-02 | 2015-04-28 | Novartis Ag | Choline salt of an anti-inflammatory substituted cyclobutenedione compound |
-
2009
- 2009-03-08 UA UAA201101223A patent/UA103198C2/ru unknown
- 2009-07-30 US US12/512,609 patent/US7989497B2/en active Active
- 2009-07-31 AR ARP090102946A patent/AR075071A1/es active IP Right Grant
- 2009-08-02 JO JO2009284A patent/JO2910B1/en active
- 2009-08-03 CA CA2732932A patent/CA2732932C/en not_active Expired - Fee Related
- 2009-08-03 NZ NZ590708A patent/NZ590708A/en not_active IP Right Cessation
- 2009-08-03 SI SI200930897T patent/SI2310359T1/sl unknown
- 2009-08-03 TW TW098126079A patent/TWI430791B/zh not_active IP Right Cessation
- 2009-08-03 CN CN200980139076XA patent/CN102171183B/zh not_active Expired - Fee Related
- 2009-08-03 JP JP2011521556A patent/JP5303645B2/ja not_active Expired - Fee Related
- 2009-08-03 ES ES09804555.2T patent/ES2458596T3/es active Active
- 2009-08-03 MY MYPI2011000324A patent/MY155626A/en unknown
- 2009-08-03 EP EP09804555.2A patent/EP2310359B1/en active Active
- 2009-08-03 EA EA201100299A patent/EA020374B1/ru not_active IP Right Cessation
- 2009-08-03 UY UY0001032025A patent/UY32025A/es not_active Application Discontinuation
- 2009-08-03 RS RS20140177A patent/RS53264B/en unknown
- 2009-08-03 WO PCT/EP2009/060061 patent/WO2010015613A1/en active Application Filing
- 2009-08-03 PT PT98045552T patent/PT2310359E/pt unknown
- 2009-08-03 KR KR1020117005082A patent/KR101310503B1/ko active IP Right Grant
- 2009-08-03 PE PE2011000121A patent/PE20110205A1/es active IP Right Grant
- 2009-08-03 AU AU2009279123A patent/AU2009279123B2/en not_active Ceased
- 2009-08-03 MX MX2011001378A patent/MX2011001378A/es active IP Right Grant
- 2009-08-03 PL PL09804555T patent/PL2310359T3/pl unknown
- 2009-08-03 DK DK09804555.2T patent/DK2310359T3/da active
- 2009-08-03 BR BRPI0916995A patent/BRPI0916995B8/pt not_active IP Right Cessation
-
2011
- 2011-01-20 ZA ZA2011/00512A patent/ZA201100512B/en unknown
- 2011-01-24 IL IL210836A patent/IL210836A/en active IP Right Grant
- 2011-02-01 MA MA33576A patent/MA32536B1/fr unknown
- 2011-02-01 CO CO11011417A patent/CO6341623A2/es active IP Right Grant
- 2011-02-03 HN HN2011000341A patent/HN2011000341A/es unknown
- 2011-02-03 EC EC2011010804A patent/ECSP11010804A/es unknown
- 2011-02-04 CU CU2011000030A patent/CU24038B1/es active IP Right Grant
- 2011-02-04 SV SV2011003831A patent/SV2011003831A/es unknown
- 2011-06-21 US US13/165,048 patent/US8288588B2/en active Active
- 2011-06-21 US US13/165,060 patent/US8329754B2/en active Active
- 2011-06-24 CU CU20110142A patent/CU20110142A6/es unknown
- 2011-09-08 HK HK11109517.2A patent/HK1155151A1/xx not_active IP Right Cessation
-
2012
- 2012-09-12 US US13/611,446 patent/US8722925B2/en active Active
-
2014
- 2014-04-01 US US14/242,434 patent/US9115087B2/en active Active
- 2014-04-14 HR HRP20140350AT patent/HRP20140350T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20110030A7 (es) | Compuestos orgánicos | |
ECSP12011909A (es) | Derivados de glicósido y usos de los mismos | |
UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
CO6470845A2 (es) | Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales | |
ECSP11010880A (es) | Compuestos orgánicos | |
CR20120328A (es) | Compuestos antiparasitarios de dihidroazol y composiciones que comprenden a los mismos | |
NI201000013A (es) | Sulfonamidas como moduladores del trpm8 | |
UY32142A (es) | Preparación de una quinoliniloxidifenilciclopropanodicarboxamida | |
UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов | |
UY31162A1 (es) | Espiroindolinas como moduladores de receptores de quimioquinas | |
EA201170997A1 (ru) | Производные индола в качестве противораковых агентов | |
UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
DOP2009000214A (es) | Macrolidos basados en eritromicina | |
UY32385A (es) | Amidas de pirazinona sustituida | |
CO6430464A2 (es) | Derivados de amida como ligandos del receptor y5 del neuropéptido | |
UY32447A (es) | Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia | |
TN2011000035A1 (en) | Organic compounds | |
CY1115028T1 (el) | Οργανικες ενωσεις | |
CU20080116A7 (es) | 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas | |
CU23642B7 (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |